How to access Epkinly from Saudi Arabia, the named-patient import pathway, 2026
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-13.
A Saudi patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, or relapsed or refractory follicular lymphoma after two or more lines of systemic therapy may receive a prescription for Epkinly (epcoritamab-bysp) from their treating hematologist. The product is FDA-approved in the United States and co-developed by AbbVie and Genmab (the brand name in the European Union is Tepkinly). It is a CD3xCD20 T-cell engaging bispecific antibody administered by subcutaneous injection. Local availability of Epkinly in Saudi Arabia can be inconsistent: the drug may not be on every hospital pharmacy's standing hematology formulary, the specific indication may not match what is locally registered, or the strength required may be back-ordered. When that happens, a named-patient import pathway through the Ministry of Public Health (MoPH) remains a legitimate route for the patient whose physician has already prescribed the drug.
This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.
Ask about Epkinly in Saudi Arabia
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Epkinly is a humanised IgG1 bispecific antibody that simultaneously engages CD3 on T-cells and CD20 on malignant B-cells, redirecting cytotoxic T-cell activity to lymphoma cells. The regimen uses a step-up dosing schedule on cycle 1 to mitigate cytokine release syndrome (CRS), with full-dose subcutaneous injections continuing on a weekly, then every-other-week, then every-four-week cadence depending on cycle. Baseline workup per FDA labeling includes complete blood count with differential, hepatic function tests, hepatitis B serology, neurologic baseline assessment, and pregnancy testing where applicable. The FDA boxed warning covers cytokine release syndrome and neurologic toxicity including immune effector cell-associated neurotoxicity syndrome (ICANS). Step-up dosing typically requires hospital admission for the first full dose. Your hematologist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Epkinly legally importable into Saudi Arabia?
Yes, through the Ministry of Public Health (MoPH) of Saudi Arabia named-patient and personal-use import framework, coordinated with the treating facility's pharmacy. Saudi Arabia has an established pathway for specialty hematology medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.
The MoPH named-patient route allows a Saudi Arabia-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility. For bispecific antibodies with boxed warnings on CRS and ICANS, MoPH reviewers typically expect documentation of the admitting facility's CRS management protocol.
How the pathway works, step by step
- Consultation with your treating hematologist. The prescribing decision is clinical. Your hematologist documents the indication, prior therapies (including any prior CAR-T or stem cell transplant), and rationale for Epkinly.
- Baseline screening. CBC, LFTs, hepatitis B serology, neurologic baseline, and pregnancy testing where applicable are confirmed and documented. The admitting facility's CRS management protocol is identified.
- MoPH named-patient application. Your hematologist or the hospital's import pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure product from AbbVie and Genmab's authorised distribution under DSCSA chain-of-custody.
- Cold-chain shipment. Epkinly requires refrigerated transport at 2 to 8 degrees Celsius. Shipments include temperature-monitored packaging with continuous loggers and tamper-evident seals.
- Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription, and your hematologist initiates therapy with step-up dosing in the inpatient setting.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming diagnosis (DLBCL or follicular lymphoma subtype, prior lines, prior CAR-T or transplant status) and Epkinly as the indicated next step
- Verification of their Saudi Arabia medical licence (Saudi Arabia Council for Healthcare Practitioners registration)
- A patient identifier, anonymised reference where privacy is preferred
- Documented pre-treatment screening (CBC, LFTs, hepatitis serology, neurologic baseline) consistent with FDA labeling
- The planned step-up dosing schedule and the admitting facility's CRS and ICANS management protocol
- A discussion note on the boxed-warning monitoring plan for cytokine release syndrome and neurologic toxicity
Reserve Meds provides a physician documentation kit that bundles the templates MoPH reviewers expect to see for CD3xCD20 bispecific antibodies, including the CRS and ICANS monitoring plan reviewers commonly request.
Typical costs and indicative timing
Reserve Meds gives you a transparent, itemised custom quote at intake. Medicine price: quote on request. You get a written quote for your case before you commit. Subsequent cycles run lower as dosing intervals lengthen. International logistics, MoPH documentation handling, cold-chain shipping, and coordination add incremental cost. The delivered quote we issue at intake shows each line separately.
We give you a written timeline estimate for your case before you commit. Refills ship on a rolling cadence aligned to your dosing schedule.
Where Reserve Meds fits in
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Epkinly specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
- Documentation. Regulatory package tailored for your physician and for MoPH review, including bispecific-class CRS and ICANS monitoring templates.
- Cold-chain logistics. Temperature-monitored, internationally tracked shipment to your named dispensing facility with continuous temperature loggers.
- Dedicated case lead. A named point of contact for your family and your physician across the full case arc.
We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating hematologist, and dispensing sits with the licensed Saudi pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.
Frequently asked
Is this legal in Saudi Arabia? Yes, when executed through the MoPH named-patient framework with appropriate documentation, clinical rationale, and a licensed dispensing facility with a CRS-capable inpatient unit. The pathway is routinely used in Saudi hematology centers.
Is this the same drug as Tepkinly? Yes. The active ingredient is epcoritamab-bysp. The brand name in the United States is Epkinly. The brand name in the European Union is Tepkinly. The product Reserve Meds sources is the FDA-approved Epkinly under DSCSA chain-of-custody from the US.
What about the boxed warning? The FDA boxed warning on epcoritamab covers cytokine release syndrome and neurologic toxicity (ICANS). The first full dose is typically administered with hospital admission for monitoring. Your hematologist performs the risk-benefit assessment and schedules CRS surveillance per labeling. Reserve Meds does not make that clinical judgement, your physician does.
Will my private health insurance cover this? Cash-pay is the default posture. Some Saudi private insurers reimburse named-patient hematology imports on a case-by-case basis when the documentation package is strong. We supply documentation for your submission but do not process insurance claims.
What if my hematologist has not filed a named-patient request before? Named-patient import is an institutional process most major Saudi oncology centers (King Faisal Specialist Hospital and Research Centre (KFSHRC) Riyadh, National Guard Health Affairs (NGHA), King Fahad Medical City (KFMC), King Abdulaziz Medical City (KAMC), and King Faisal Specialist Hospital Jeddah) have encountered. Our documentation kit is written for first-time applicants and tracks what MoPH reviewers commonly ask for.
Next step
For Epkinly coordination in Saudi Arabia, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Composite case examples. This content is for general information and does not constitute medical advice.
Regulatory status of Epkinly in Saudi Arabia, 2026
Epkinly (epcoritamab-bysp) is not currently held on the locally registered medicines list of the Saudi Food and Drug Authority (SFDA). The product is approved by the US Food and Drug Administration per the labelled indication of relapsed or refractory diffuse large B-cell lymphoma not otherwise specified and high-grade B-cell lymphoma after two or more lines of systemic therapy, and relapsed or refractory follicular lymphoma after two or more lines of systemic therapy (see the FDA label at accessdata.fda.gov). The European Medicines Agency holds a parallel marketing authorisation where applicable (see the EMA EPAR at ema.europa.eu).
Because Epkinly is not on the SFDA locally registered list, access for a Saudi Arabia-based patient runs through the named-patient and personal-import framework that the SFDA maintains for reference-authority-approved medicines that are not held locally. The official SFDA portal is at www.sfda.gov.sa/en. The qualifying conditions are well established: the medicine is approved by a recognised reference authority (FDA or EMA qualifies); no locally available alternative is clinically equivalent for the specific patient indication; the treating physician of record takes documented clinical responsibility; and chain of custody is preserved end to end from the US source through international transit to the named dispensing facility.
The named-patient and personal-import pathway is the routine framework. For a complex cell or gene therapy that requires a US-certified treatment center, the practical route is patient travel to that certified center rather than import into Saudi Arabia; see Block 2 below for the operational shape on that case type.
Tertiary centers and clinical coordination in Saudi Arabia
The Saudi Arabia tertiary referral network for a Epkinly case is concentrated at King Faisal Specialist Hospital and Research Centre (KFSHRC), King Abdulaziz Medical City (KAMC), and King Fahad Medical City (KFMC). These centers carry the haematology, oncology, paediatric subspecialty, or rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For cellular and gene therapies that require leukapheresis collection, AAV infusion, or post-treatment monitoring of a complexity beyond what a community centre is configured for, the case is routinely referred to one of these tertiary centers from the outset.
For cell and gene therapies specifically, the practical access pathway runs through patient travel to a US-certified treatment center (Casgevy authorised treatment centers, Yescarta certified centers, Abecma certified centers, Zolgensma certified centers, Elevidys treatment centers, Hemgenix treatment centers, and so on) rather than import of the cellular or AAV product into Saudi Arabia. The tertiary Saudi Arabia centers handle the upstream referral package assembly (clinical summary, pathology, imaging, organ function panel, infectious disease screen, performance status), the US-side coordination, and the long-term follow-up after the patient returns home. Reserve Meds coordinates the cross-border arc between the Saudi Arabia tertiary team and the US treatment center, including travel and accommodation logistics, financial clearance, and post-treatment data flow.
For oral kinase inhibitors and antibody therapies that can be administered in Saudi Arabia once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Medicines are supplied through a US-licensed pharmaceutical wholesale partner under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, and Reserve Meds coordinates international shipment to the named dispensing facility and re-supply aligned to the dosing schedule.
Saudi Arabia quotes and payer posture, 2026
Reserve Meds issues a written, itemised custom quote once your treating physician's documentation is in. Medicine price: quote on request. You get a written quote for your case before you commit.
Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, US treatment center facility and physician fees where applicable, Reserve Meds coordination, and any patient and caregiver travel and accommodation are itemised separately. For a cell or gene therapy case the total course cost includes US treatment center fees, lymphodepletion or pre-infusion conditioning, inpatient monitoring, complication management, and family travel and accommodation, as well as the medicine.
Payer posture in Saudi Arabia is overwhelmingly cash-pay for named-patient imports and cross-border CAR-T cases. Public coverage (CCHI essential drug list at https://www.cchi.gov.sa) generally does not extend to non-locally-registered specialty cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.
Access barriers and how Reserve Meds clears them
The five access barriers we see most often for a Epkinly case in Saudi Arabia are: (1) Regulatory documentation complexity. The SFDA named-patient and personal-import application package requires a specific bundle (physician clinical rationale letter, prescription, patient identifier, product strength and quantity, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent for the patient). Reserve Meds provides physician-facing templates that match the format SFDA reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with US-licensed pharmaceutical wholesale partners to secure Epkinly from authorised distribution under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.
(3) For cell and gene therapies, the US-certified treatment center qualification gate. Casgevy, Yescarta, Carvykti, Abecma, Zolgensma, Elevidys, Hemgenix, and Luxturna can only be administered at a manufacturer-certified treatment center. Reserve Meds maintains the referral arcs to the appropriate US-certified centers and handles the referral package routing, financial clearance, and the multi-week stay coordination. (4) Family logistics. Patient and caregiver travel, accommodation near the treatment center, in-US transport, translator support where needed, and post-treatment data flow back to the treating Saudi Arabia physician are coordinated as a single arc. (5) Insurance and payer posture. Cash-pay is the default. Where private insurance review is contemplated, we supply documentation for the family's submission but we do not bill insurers and we do not adjudicate insurance disputes.
Drug-specific clinical context for Epkinly: the labelled indication is relapsed or refractory diffuse large B-cell lymphoma not otherwise specified and high-grade B-cell lymphoma after two or more lines of systemic therapy, and relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. The relevant clinical-practice guideline body is NCCN B-cell lymphoma guidelines at www.nccn.org. Your treating physician of record makes the clinical decision; Reserve Meds is the coordination layer that clears the operational and regulatory barriers between the prescription and the delivered course.
Recent regulatory and access news for Epkinly in Saudi Arabia, 2026
The Saudi Food and Drug Authority (SFDA) portal at www.sfda.gov.sa/en has not posted a Epkinly-specific listing on the publicly searchable locally registered medicines list at www.sfda.gov.sa/en/drugs-list as of 2026-06-04. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages have not registered a Epkinly-specific safety advisory or shortage signal over the most recent 12-month window. The FDA labelled indication remains relapsed or refractory diffuse large B-cell lymphoma not otherwise specified and high-grade B-cell lymphoma after two or more lines of systemic therapy, and relapsed or refractory follicular lymphoma after two or more lines of systemic therapy (see the current label at accessdata.fda.gov). AbbVie in collaboration with Genmab continues commercial supply per the FDA-labelled indication and the EMA marketing authorisation. The NCCN B-cell lymphoma guidelines guidance at www.nccn.org remains the relevant clinical-practice reference. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.
Frequently asked questions
How can I get Epkinly in Saudi Arabia if it is not approved or available there?
Reserve Meds coordinates US-sourced Epkinly for patients in Saudi Arabia through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for Saudi Arabia and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Epkinly in Saudi Arabia through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Epkinly. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in Saudi Arabia, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Epkinly in Saudi Arabia through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Epkinly to a patient in Saudi Arabia?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Epkinly to your treating physician or hospital pharmacy in Saudi Arabia, with appropriate handling for the product.
How long does it take, and what does Epkinly in Saudi Arabia cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Epkinly in Saudi Arabia?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.